The following abstracts were printed in the December 15, 2012 SABCS abstract supplement to Cancer Research, but were withdrawn by the authors before the start of the symposium:

P1-01-07:  The Institut Curie Nomogram including HER2 status predicts additional axillary metastasis in breast cancer patients with a positive sentinel node biopsy: a multicentric validation. Ngo C, De Rycke Y, Belichard C, Guilhen N, Doridot V, Rouzier R, Coutant C, Hudry D, Fritel X, Fourchotte V, Feron J-G, Pierga J-Y, Salomon A, Alran S.

P1-04-11:  EZH2 expands breast stem cells via NOTCH signaling, acting to accelerate breast cancer initiation. Kleer CG, Li X, Moore HM, Toy KA, Gonzalez ME.

P1-05-17:  S100A7/RAGE axis enhances breast cancer growth by activating Stat3 signaling. Nasser MW, Wani NA, Qamri Z, Ahirwar D, Powell CA, Ganju RK.

P1-15-08:  Higher toxicity of docetaxel for obese women with early breast cancer: lean body mass is a significant predictor of chemotherapy dose intensity reduction. Gouerant S, Clatot F, Modzlewski R, Chaker M, Rigal O, Veyret C, Leheurteur M.

P1-15-09:  Multi-institutional evaluation of bioimpedance spectroscopy (BIS) in the early detection of breast cancer related lymphedema. Vicini F, Arthur D, Shah C, Anglin BV, Curcio L, Laidley AL, Beitsch P, Whitworth P, Lyden M.

P2-05-16:  Expression of β-III tubulin, foxo 3 protein and deoxythymidine kinase in breast cancer patients receiving neoadjuvant chemotherapy. Chow LWC, Loo WTY, Yip AYS, Ong EYY, Ng W-K.

P2-09-03:  Identifying a landscape of DNA methylation-driven genes in breast cancer using MethylMix. Gevaert O, Plevritis S.

P2-09-05:  Screening of significantly hypermethylated genes in breast cancer using MIRA-based microarray and identifying their expression levels. Lian Z-q, Wang Q, Li W-p, Zhang A-q, Wu L.

P3-02-04:  Screen detected HER2 positive breast cancer within the West of London Breast Screening population: Incidence, management and outcome. O'Cathail S, White A, Brindley JH, Hadjiminas D, Xynos Y, Cleator S, Hogben K, Palmieri C.

P3-06-21:  Unique molecular subtypes of triple negative breast carcinomas by routine IHC: implications for treatment and prognosis. Ashfaq R, Wright B, Russell K, Voss A.

P3-09-05:  The role of breast size in detection of breast cancer in Asian women. Lee S, Sandhu H, Zheng Y. Holy Name Medical Center

P4-03-09:  A comparison of MRI, PET-CT, and ultrasonography for evaluation of tumor response to neoadjuvant chemo-therapy in patients with locally advanced breast cancer. Boothe DL, Stessin A, Nagar H, Hayes MK.

P4-06-09:  Cell surface receptor CDCP1 as a potential marker of triple negative breast cancers progression. Campiglio M, Sasso M, Bianchi F, De Cecco L, Turdo F, Triulzi T, Orlandi R, Morelli D, Aiello P, Ghirelli C, Agresti R, Tagliabue E.

P4-06-12:  Monoclonal antibodies against nicastrin for the treatment of breast cancer: in vitro and in vivo characterisation and function. Filipovic A, Lombardo Y, Deonarain M, Giamas G, Cordingley H, Tralau-Stewart C, Coombes RC.

P4-09-12:  TIMP-4 – prognostic marker and treatment target for triple-negative breast cancers. Wallon UM, Sabol JL, Gilman PB, Zemba-Palko V, DuHadaway JB, Ciocca RM, Ali ZA, Carp NZ, Choy NS, Wojciechowski BS, Prendergast GC.

P4-12-02:  Serum 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: the Multiethnic Cohort Study. Kim Y, Franke AA, Shvetsov YB, Wilkens LR, Lurie G, Cooney RV, Maskarinec G, Hernandez BY, Le Marchand L, Henderson B, Kolonel LN, Goodman MT.

P4-15-04:  Impact of awake breast cancer surgery on postoperative lymphocyte responses. Vanni G, De Felice V, Buonomo C, Esser A, Petrella G, Buonomo OC.

P4-17-02:  Radiation therapy and expander-implant breast reconstruction: an analysis of timing and comparison of complications. Lentz RB, Higgins SA, Matthew MK, Kwei SL.

P5-07-06:  Triple negative receptor status is associated with low DNA repair capacity in women with breast cancer. Matta J, Ortiz C, Vargas W, Echenique M, Sanchez F, Ramirez E, Torres A, Ortiz J, Bolaños G, Gonzalez J, Laboy J, Barnes R, Santiago S, Romero A, Martinez R, Alvarez-Garriga C, Bayona M.

P6-02-03:  Mouse models of breast cancer identify oncogene-specific stroma associated with human breast cancer molecular subtypes. Saleh SM, Laferriere J, Cory S, Souleimanova M, Zacksenhaus E, Muller W, Hallett M, Park M.

P6-04-13:  HOXB7 functions as a co-activator of estrogen receptor in the development of tamoxifen resistance. Jin K, Teo WW, Yoshida T, Park S, Sukumar S.

P6-14-01:  Estrogen/progestogen use after breast cancer – a long-term follow-up of the Stockholm randomized trial. Fahlén MC, Fornander T, Johansson H, Rutqvist L-E, Wilking N, von Schoultz E.

PD08-01:  Utilization of Oncotype DX in an inner-city population: Race or place? Guth AA, Fineberg S, Fei K, Franco R, Bickell N.

The following abstracts were listed as “Withdrawn” in the SABCS Pocket Program and the print December 15, 2012 SABCS abstract supplement to Cancer Research and have been reinstated.


New high-quality HER2 IQFISH pharmDx assay with a ½ working day procedure and high concordance to HER2 FISH pharmDx. Jensen K, Nielsen KV, Andresen L, Müller S, Mollerup J, Matthiesen SH, Schønau A. Dako A/S, Glostrup, Denmark; Dako Denmark, Glostrup, Denmark

Introduction: HER2 assessment for selection of patients that may benefit from HER2 targeting treatment can be conducted by either immunohistochemistry (IHC), fluorescence, or chromogen in situ hybridization (FISH or CISH). FISH is a robust and reliable technique for direct visualization and quantitative determination of gene amplifications, deletions, and translocations in human cancer cells, but FISH protocols are time-consuming and involve toxic reagents. By introducing a new nontoxic ethylene carbonate-based hybridization buffer that can perform with very short hybridization times, the total FISH assay time on breast cancer tissue sections can be reduced from the traditional 16 to 20 hours to 3½ to 4½ hours.

Material and methods: The new Dako HER2 IQFISH pharmDx was compared with Dako HER2 FISH pharmDx in a comparative study on 120 breast cancer specimens, and reproducibility of the HER2 IQFISH pharmDx assay was investigated in a study comprising 3 different sites and a total of 6 different observers. Samples for the comparative study was evaluated by Dako HercepTest to include all IHC scoring groups (0, 1+, 2+, 3+). Slides were stained according to manufacturer's instructions using microwave oven for heat pretreatment and RTU pepsin for 3 to 5 minutes at 37°C. Hybridization was conducted for 2 hours when using HER2 IQFISH pharmDx and for 17 to 20 hours when using HER2 FISH pharmDx Kit. All slides were blinded before evaluation. HER2 status was classified as “nonamplified” when the HER2/CEN17 ratio was less than 2.0 and “amplified” when the HER2/CEN17 ratio was 2.0 or more.

Results: The new nontoxic hybridization buffer introduces a major safety improvement since formamide is no longer needed. Significantly shorter hybridization times are required to generate the same signal intensity (1–2 hour hybridization versus overnight). HER2 IQFISH pharmDx was compared with the traditional HER2 FISH pharmDx in a comparative study on 120 breast tissue specimens of human breast carcinoma. The preliminary data on HER2 status for 78 patients obtained by the 2 assays gave an overall agreement of 98.7% with lower and upper 95% confidence limits at 94.2% and 99.9%. The κ value was 0.96 (95% CL: 0.89–1.00). The P value for McNemars test was 1.00 indicating absence of bias between the 2 assays. Disagreement between the 2 assays was observed for one specimen—a heterogeneous tissue with a small amplified area. Data from the reproducibility study that included site-to-site variation, day-to-day variation, and interobserver variation showed that the assay has a high degree of reproducibility.

Conclusion: The validation studies of the new HER2 IQFISH pharmDx showed a very high concordance to the traditional HER2 FISH pharmDx and also that the assay is robust and reproducible. Reduction of the overall assay time from a 2-day to a half-day procedure for HER2 FISH, offers more flexible laboratory routines and same day reporting for all working days of the week, which could be used for fast and simultaneous FISH and IHC answers and improved patient care. Taken together, the study shows the potential of a new revolutionary platform that enables optimization and acceleration of FISH analysis to the benefit of patients with cancer and laboratory personnel.


Comparison of efficacy of primary prophylaxis with pegfilgrastim, filgrastrim, and a biosimilar filgrastim in TAC regimen (docetaxel, doxorubicin, and cyclophosphamide). Brito M, Esteves S, Andre R, Isidoro M, Moreira A. Portuguese Cancer Institute Francisco Gentil, Lisbon, Portugal

Background: Febrile neutropenia is a major toxicity of myelosupressive chemotherapy. Primary prophylactic use of granulocyte colony-stimulating factors (G-CSF) is recommended in high-risk febrile neutropenia regimens. The comparison of pegfilgrastim (Peg) and filgrastim (Fil) febrile neutropenia prophylactic effectiveness is still an issue of debate. Very recently Nivestim (Niv), a new biosimilar filgrastim, has also become commercially available. We aimed to compare the efficacy of the 3 mentioned types of G-CSF in the primary prophylaxis of febrile neutropenia.

Methods: Single-center, retrospective study to evaluate the incidence of febrile neutropenia in women with breast cancer treated with adjuvant or neoadjuvant TAC (febrile neutropenia risk ≥20%). Patients (Pt) were divided in 3 consecutive cohorts according to G-CSF primary prophylaxis (Fil, Peg, and Niv). Febrile neutropenia was defined as axillary temperature of 38.3°C or more and absolute neutrophil count less than 500/μL.

Results: We included a total of 421 women (median age, 51 y; range, 25–76) with stage II (56%) and stage III (44%) breast cancer. Age and stage distribution were similar in the 3 cohorts. A single dose of Peg was administered in all 767 cycles (Cy). The standard dose of Fil and Niv was 7 daily injections, only in 13% Fil patients and in 10% Niv patients, less than 7 administrations were done. The incidence of febrile neutropenia per patient and per cycle is presented in Table 1. In all cohorts, approximately half of NF episodes occurred in the first cycle (48% Fil, 59% Peg, 42% Niv).

Table 1.

Incidence of febrile neutropenia per patient and per cycle

(147 pts; 840 cy)(140 pts; 767 cy)(134 pts; 710 cy)Fisher test
% Pt febrile neutropenia 15.6% (23/147) 8.6% (12/140) 13.4% (18/134) Niv vs. Peg 
 IC95%: 10.4–2.8% IC95%: 4.5–14.5% IC95%: 8.2–20.4% P = 0.25 
    Niv vs. Fil 
    P = 0.62 
    Fil vs. Peg 
    P = 0.07 
% Cy febrile neutropenia 3.2% (27/840) 2.2% (17/767) 3.7% (26/710) Niv vs. Peg 
 95% CI: 2.2–4.7% 95% CI: 1.3–3.5% 95% CI: 2.4–5.3% P = 0.12 
    Niv vs. Fil 
    P = 0.68 
    Fil vs. Peg 
    P = 0.28 
(147 pts; 840 cy)(140 pts; 767 cy)(134 pts; 710 cy)Fisher test
% Pt febrile neutropenia 15.6% (23/147) 8.6% (12/140) 13.4% (18/134) Niv vs. Peg 
 IC95%: 10.4–2.8% IC95%: 4.5–14.5% IC95%: 8.2–20.4% P = 0.25 
    Niv vs. Fil 
    P = 0.62 
    Fil vs. Peg 
    P = 0.07 
% Cy febrile neutropenia 3.2% (27/840) 2.2% (17/767) 3.7% (26/710) Niv vs. Peg 
 95% CI: 2.2–4.7% 95% CI: 1.3–3.5% 95% CI: 2.4–5.3% P = 0.12 
    Niv vs. Fil 
    P = 0.68 
    Fil vs. Peg 
    P = 0.28 

Conclusions: No differences in terms of efficacy existed between Biosimilar Niv and original biologic reference filgrastim. Seven daily injections of filgrastim and Nivestim seem equivalent to single dose Pegfilgrastim. Besides efficacy, questions like cost-effectiveness and convenience of administration should be taken into account when approaching this topic. Our data showed a predominance of events in the first cycle (regardless of the type of G-CSF). This has been consistently described in the literature and may support the necessity to recommend other NF preventive measures in this cycle.

The following abstracts were printed in the December 15, 2012 SABCS abstract supplement to Cancer Research, but were not presented at the symposium:

P1-01-25:  Sentinel lymph node biopsy in breast cancer: The approach in day surgery under local anaesthesia for quality-of-life and significant cost reduction. Ricci F, Capuano LG, Saralli E, Di Legge P, Violante A, Polistena A, Scala T, Pacchiarotti A, Cannas P, Cianni R, Fanelli G, Bellardini P, De Masi C.S.M.

P1-03-01:  Evidence for the Warburg effect in mammary atypia from high-risk African American women. Seewaldt V, Hoffman A, Ibarra-Drendall C.

P1-04-04:  KSR1 is involved in functional interaction between p53 and BRCA1 and is an independent predictor of overall survival in breast cancer. Zhang H, Lombardo Y, Filipovic A, Periyasamy M, Coombes RC, Stebbing J, Giamas G.

P1-04-05:  Role of the Rb and p53 tumor suppressor pathways in mammary tumorigenesis. Jones RA, Liu JC, Zhe J, Schimmer AA, Eldad Z.

P1-05-08:  Targeting integrin signaling suppresses invasive recurrence in a three-dimensional model of radiation treated ductal carcinomain situ. Nam J-M, Ahmed KM, Costes S, Zhang H, Sabe H, Shirato H, Park CC.

P1-13-07:  Association between delayed initiation of adjuvant chemotherapy and survival in breast cancer: a single-institution study and a systematic review and meta-analysis. Yu K-D, Fan L, Yang C, Shao Z-M. Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.

P2-06-07:  Exome sequencing identifies somatic mutations in basal-like breast cancer before and after neoadjuvant chemotherapy. Jiang Y-Z, Yu K-D, Shao Z-M. Shanghai Cancer Center, Shanghai, Shanghai, China.

P2-09-05:  Screening of significantly hypermethylated genes in breast cancer using MIRA-based microarray and identifying their expression level. Lian Z-q, Wang Q, Li W-p, Zhang A-q, Wu L. Breast Disease Center, Guangdong Women and Children Hospital of Guangzhou Medical College.

P2-09-06:  The structure design and biological activities of inhibitory peptides, which block the interactions among polycomb repressive complex 2. LI KK, Luo L, Kong X, Li L, Luo C. Rui Jin Hospital Affiliated with the Shanghai JiaoTong University School of Medicine, 197 Rui Jin Road II, Shanghai, China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, Shanghai, China.

P2-10-26:  Association between circulating tumor cells and molecular breast cancer subtypes. Gang N, Haibo W, Funian L, Chen L, Xiaoyi L, Xingang W, Zhidong L. Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong, China.

P3-02-08:  Is repetition of the contralateral mammogram of patients referred from breast cancer screening for unilateral findings necessary? Castro C, Schipper R-J, van Roozendaal L, van Goethem M, Lobbes M, Smidt M. Maastricht University Medical Center, Maastricht, Netherlands; Antwerp University Hospital, Antwerp, Belgium.

P3-10-03:  Bartonella henselae infection detected in patients with inflammatory breast cancer. Fernandez SV, Aburto L, Maggi R, Breitschwerdt EB, Cristofanilli M. Fox Chase Cancer Center, Philadelphia, PA; North Caroline State University, Raleigh, NC.

P3-10-04:  Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase. Lehman HL, Van Laere SJ, van Golen CM, Vermeulen PB, Dirix LY, van Golen KL. The University of Delaware, Newark, DE; Sint Augustine Hospital, Antwerp, Belgium; Catholic University, Leuven, Belgium; Delaware State University, Dover, DE.

P3-10-08:  A new in vitro method of growing and studying inflammatory breast cancer emboli. Lehman HL, Daasner EJ, Vermeulen PB, Dirix LY, Van Laere S, van Golen KL. The University of Delaware, Newark, DE; Sint Augustine Hospital, Antwerp, Belgium; Catholic University, Leuven, Belgium.

P3-12-07:  Voyagers and their aids: The role of interactions between tumor and endothelial cells in brain metastasis. Shah KN, Faridi JS. University of the Pacific, Stockton, CA.

P3-12-12:  Chemotherapy and targeted therapy after whole-brain radiotherapy may improve survival in RPA class II/III patients with brain metastases from breast cancer. Zhang Q, Chen J, Cai G, Yang Z, Chen J. Fudan University Shanghai Cancer Center, Shanghai, China.

P4-01-01:  Integrating dynamic magnetic resonance imaging and gene expression profiling reveals novel therapeutic targets in locally advanced breast cancer. Hughes NP, Mehta S, Winchester L, Han C, Buffa FM, Adams RF, Harris AL. Stanford University, Stanford, CA; University of Oxford, United Kingdom; Churchill Hospital, Oxford, United Kingdom.

P4-02-08:  Quantitative characterization of 3D vasculature spatial patterns within tumor microenvironment of breast cancer stem cells. Zhan M, Li F, Zhu Y, Ma J, Landua J, Wei W, Vadakkan T, Zhang M, Dickinson M, Lewis M, Rosen J, Wong S. NCI Center for Modeling Cancer Development, The Methodist Hospital, Houston, TX; Baylor College of Medicine, Houston, TX.

P4-03-09:  A comparison of MRI, PET-CT, and ultrasonography for evaluation of tumor response to neoadjuvant chemo-therapy in patients with locally advanced breast cancer. Boothe DL, Stessin A, Nagar H, Hayes MK. Weill Cornell Medical College, New York, NY.

P4-04-07:  Tartrate-resistant acid phosphatase (TRAcP)-expressed tumor-associated macrophages promote breast cancer progression. Dai M-S, Wu C-C, Chang P-Y, Ho C-L, Hsieh Y-F, Lo K-Y, Kao W-Y, Chao T-Y, Yu J-C. Tri-Service General Hospital, Taipei, Taiwan; Taipei Medical University, Taipei, Taiwan.

P4-07-04:  Methioninase cell-cycle synchronization potentiates chemotherapy for breast cancer. Yano S, Li S, Han Q, Tan Y, Fujiwara T, Hoffman RM. AntiCancer Inc., San Diego, CA; Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan; University of California, San Diego, CA.

P4-08-10:  Systematic expression analysis of the genes related to drug-resistance in isogenic docetaxel- and adriamycin-resistance breast cancer cell lines. Tang J, Li W, Zhong S, Xu J, Zhao J. Jiangsu Cancer Hospital, Nanjing, Jiangsu, China; Jiangsu Cancer Hospital, Nnajing, Jiangsu, China.

P4-15-01:  Second conservative treatment for ipsilateral breast tumor recurrence: GEC-ESTRO Breast WG study. Hannoun-Levi J-M, Resch A, Gal J, Niehoff P, Loessl K, Kovács G, Van Limbergen E, Polgar C. Antoine Lacassagne Cancer Center, Univerity of Nice-Sophia, Nice, France; Medical University, General Hospital of Vienna, Austria; Antoine Lacassagne Cancer Center, Nice, France; University Erlangen-Nuremberg, Erlangen, Germany; University Hospital Bernes, Switzerland; University Hospital Schleswig-Holstein Campus Lübeck, Germany; University Hospital Gasthuisberg, Leuven, Belgium; National Institute of Oncology, Budapest, Hungary.

P4-15-03:  Patterns of relapse following re-irradiation of the breast using partial breast brachytherapy (PBB). Chadha M, Boachie-Adjei K, Boolbol SK, Kirstein L, Osborne MP, Tarter P, Harrison LB. Beth Israel Medical Center, New York, NY.

P4-17-08:  Tissue expander/implant breast reconstruction with and without postmastectomy radiation: predictive factors for complications. Nguyen SKA, Oxley P, Rastegar R, Joffres M, Kwan W. British Columbia Cancer Agency, Fraser Valley Cancer Centre; University of British Columbia; Simon Fraser University.

P5-03-14:  Expression of ALDH1 in metastasizing axillary lymph nodes in breast cancer. Shi A, Dong Y, Bi L, Xu N, Fan Z, Li S, Yang H, Li Y. First Hospital of Bethune Medical College, Jilin University, Changchun, Jilin, China; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.

P5-05-04:  Intraductal delivery of RNAi-based therapeutics to gene targets identified through computational systems modeling. Brock A, Krause S, Li H, Kowalski M, Collins J, Ingber D. Wyss Institute, Harvard University, Boston, MA; Boston Children's Hospital, Boston, MA.

P5-09-01:  Evaluation of BCL2 sequence variant in Iranian women patients with breast cancer. Motahari B, Ghaffarpour M, Javadi GH, Houshmand M. Science and Research branch, Islamic Azad University, Tehran, Islamic Republic of Iran; National Institute of Genetic Engineering and Biotechnology, Tehran, Islamic Republic of Iran; Iranian Research Organization for Science and Technology, Tehran, Islamic Republic of Iran; Special Medical Center, Tehran, Islamic Republic of Iran.

P5-10-14:  MicroRNAs as biomarkers and therapeutic adjuvants for the prognosis and treatment of drug-resistant breast cancers. Chang Y-F, Panneerdoss S, Zoghi B, Pertsemlidis A, Rao M. Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, TX; UT Health Science Center at San Antonio, TX.

P5-10-15:  Genetic variants located in beta2 adrenergic receptor gene (ADRB2) and miRNA let-7 binding site alter breast cancer susceptibility: a case control analysis. Du Y, Lu J. Shanghai Cancer Center, Fudan University, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China.

P5-16-01:  Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus Sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial. Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, Miles D. University of Texas MD Anderson Cancer Center, Houston, TX; Biomira, Inc., AB, Canada; Mount Vernon Cancer Center, Northwood, Middlesex, United Kingdom.

P5-19-01:  Targeting the HER3-phosphatidyl inositol-3 kinase pathway in breast cancers. Cook RS, Morrison MM, Arteaga CL, Perou CM. Vanderbilt University, Nashville, TN; University of North Carolina.

P5-19-03:  Olaparib plus carboplatin in combination with vandetanib inhibited the growth of BRCA-wt triple negative breast tumors in mice: Outside BRCA-box. Dey N, Sun Y, De P, Leyland-Jones B. Sanford Research/USD, Sioux Falls, SD.

P5-21-03:  Concurrent loco-regional radiotherapy and trastuzumab in early-stage breast cancer: Long-term results of prospective single-institution study. Jacob J, Belin L, Pierga J-Y, Vincent-Salomon A, Dendale R, Beuzeboc P, Cottu P-H, Campana F, Fourquet A, Kirova YM. Institut Curie, Paris, France.

P6-01-05:  Enhancement of 18F-FDG uptake and glycolysis by epidermal growth factor via PI3K activation in T47D breast cancer cells. Lee EJ, Park JW, Cung Q, Jung K-H, Lee JH, Paik J-Y, Lee K-H. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

P6-02-01:  Apoptotic cell clearance lies at the interface of post-lactational involution and breast cancer. Cook RS, Stanford JC, Earp S. Vanderbilt University; University of North Carolina.

P6-04-17:  The androgen metabolite-dependent growth in hormone receptor positive breast cancer as a novel aromatase inhibitor-resistance mechanism. Hanamura T, Niwa T, Nishikawa S, Konno H, Ghono T, Kobayashi Y, Kurosumi M, Takei H, Yamaguchi Y, Ito K-I, Hayashi S-I. Graduate School of Medicine, Tohoku University, Sendai, Japan; Shinshu University School of Medicine, Matsumoto, Japan; Saitama Cancer Center, Saitama, Japan.

P6-05-03:  Targeted inhibition of recurrent PIK3CA mutations synergizes with bicalutamide in AR-expressing triple negative breast cancer. Lehmann BD, Bauer JA, Schafer JM, Tang L, Pendleton CS, Sanders ME, Pietenpol JA. Vanderbilt, Nashville, TN.

P6-07-35:  Dragonfly effect or ironic paradox: prognostic implication of postsurgical drain in breast cancer patients. Yin W, Lin Y, Shen Z, Shao Z-M, Lu J. Fudan University Shanghai Cancer Center, Shanghai, China.

P6-07-43:  The maximum standardized uptake value of 18F-FDG to prognosticate prognosis of hormone-receptor positive metastatic breast cancer. Hu X-C, Zhang (co-first author) J, Jia Z, Ragaz J, Zhang Y-J, Zhou M, Zhang Y-P. Fudan University Shanghai Cancer Center, Shanghai, China; School of Population and Public Health; University of British Columbia, Vancouver, Canada.

P6-08-07:  Quality of life of women with breast cancer: A Middle East perspective. Jassim GA, Whitford DL. Royal College of Surgeons in Ireland- Medical University of Bahrain, Busaiteen, Bahrain.

P6-10-02:  MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with breast cancer: emerging phase II results. Alvarez RH, DeMichele A, Mailliez A, Benaim E, Fingert H, Schusterbauer C, Zhang B, Melichar B. The University of Texas MD Anderson Cancer Center, Houston, TX; Abramson Cancer Center, Philadelphia, PA; Centre Oscar Lambret, Lille, Cedex 59, France; Millennium Pharmaceuticals, Inc., Cambridge, MA; Fakultní nemocnice Olomouc - Onkologická klinika, Olomouc, Czech Republic.

P6-11-01:  Intermittent high dose proton pump inhibitor improves progression free survival as compared to standard chemotherapy in the first line treatment of patients with metastatic breast cancer. Hu X, Wang B, Sun S, Chiesi A, Wang J, Zhang J, Fais S. Fudan University Shanghai Cancer Center, Shanghai, China; National Institute of Health, Roma, Italy.

P6-13-02:  Overcoming therapy resistance of metastatic breast cancer by enhanced tumor delivery of polymeric doxorubicin. Shen H, Xu R, Mai J, Huang Y, Ferrari M. The Methodist Hospital Research Institute, Houston, TX.

P6-14-05:  Impact of breast cancer CME: Physician practice pattern, knowledge, and competence assessments. Haas M, Heintz A, Stacy T. Educational Concepts Group, LLC, Atlanta, GA.

OT1-1-13:  Dual blockade with Afatinib and Trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70. Hanusch C, Schneeweiss A, Untch M, Paepke S, Kuemmel S, Jackisch C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S-D, Blohmer J-U, Loibl S, Nekljudova V, von Minckwitz G. Rotkreuzklinikum Muenchen; University Heidelberg; Helios Klinik Berlin; Frauenklinik Muenchen; Kliniken Essen Mitte; Klinikum offenbach; University Duesseldorf; Eilenriedeklinik Düsseldorf; University Rostock; University Kiel; Charite Berlin; University Magdeburg; Sankt Gertrauden Berlin; German Breast Group, Neu- Isenburg.

The following abstracts have been revised and the online versions no longer match the print December 15, 2012 SABCS abstract supplement to Cancer Research.

S2-3:  Disparities in the utilization of axillary sentinel lymph node biopsy among black and white patients with node-negative breast cancer from 2002-2007. Black DM, Jiang J, Kuerer HM, Buc

S3-2:  Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). Aebi S, Gelber S, Láng I, Anderson SJ, Robidoux A, Martín M, Nortier JWR, Mamounas EP, Geyer, Jr. CE, Maibach R, Gelber RD, Wolmark N, Wapnir IL. International Breast Cancer Study Group, Bern, Switzerland; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Breast International Group, Brussels, Belgium.

P2-10-29:  Time dependent breast cancer metastasis prediction using novel biological imaging, clinico-pathological and genomic data combined with Bayesian modeling to reduce over-fitting and improve on inter-cohort reproducibility. Sheeba I, Kelleher M, Lawler K, Festy F, Barber P, Shamill E, Gargi P, Weitsman G, Barrett J, Fruhwirth G, Huang L, Tullis I, Woodman N, Pinder S, Ofo E, Fernandes L, Beutler M, Ameer-Beg S, Holmberg L, Purushotham A, Fraternali F, Condeelis J, Hanby A, Gillett C, Ellis P, Vojnovic B, Coolen A, Ng T. Kings College London, Guy's Medical School Campus, London, England, United Kingdom; King's College London, Strand Campus, London, England, United Kingdom; Guy's and St Thomas Foundation Trust, London, England, United Kingdom; Gray Institute for Radiation Oncology & Biology, University of Oxford, England, United Kingdom; Leeds Institute of Molecular Medicine, Leeds, England, United Kingdom.

PD03-08:  Statin use and improved outcome in primary inflammatory breast cancer: retrospective cohort study. Brewer TM, Masuda H, Iwamoto T, Liu P, Shen Y, Liu DD, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT. MD Anderson Cancer Center, Houston, TX; Eastern Virginia Medical School, Norfolk, VA; University of Florida, Gainesville, FL; Okayama University Hospital, Okayama, Japan.

P3-06-03:  Association between PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients. Jørgensen CLT, Nielsen TO, Bjerre KD, Liu S, Wallden B, Balslev E, Nielsen DL, Ejlertsen B. Herlev University Hospital, Herlev, Denmark; Danish Breast Cancer Cooperative Group, Copenhagen, Denmark; University of British Columbia, Vancouver, BC, Canada; NanoString Technologies, Seattle, WA.

P3-06-34:  Plasma (p) VEGF-A and VEGFR-2 biomarker (BM) results from the BEATRICE phase III trial of bevacizumab (BEV) in triple negative early breast cancer (BC). Carmeliet P, Pallaud C, Deurloo RJ, Bubuteishvili-Pacaud L, Henschel V, Dent R, Bell R, Mackey J, Scherer SJ, Cameron D. Vesalius Research Center, Leuven, Belgium; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Genentech, Inc., South San Francisco; University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh, United Kingdom; Sunnybrook Health Sciences Center and University of Toronto, Toronto, ON, Canada; National Cancer Center, Singapore, Singapore; Andrew Love Cancer Centre, Geelong, Australia; Cross Center Institute, Edmonton, Canada.

P6-07-06:  Patterns of locoregional failure in the CALOR (Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer) Trial. Wapnir IL, Gelber S, Láng I, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Mamounas EP, Geyer, Jr. CE, Maibach R, Gelber RD, Wolmark N, Aebi S. National Surgical Adjuvant Breast and Bowel Project; International Breast Cancer Study Group; Breast International Group.